When It Comes To FTC M&A Review, The Times May Be A Changin'
Executive Summary
Spark signaled in an SEC filing that its merger with Roche could be delayed into 2020, fueling more speculation that FTC is increasing scrutiny over biopharma mergers.
You may also be interested in...
AbbVie Updates Exec Team, Creates A Separate Aesthetics Business Unit
The only addition to AbbVie’s leadership after it closes the $63bn acquisition of Allergan will be Carrie Strom, who will lead the Allergan Aesthetics business.
Allergan’s Botox Gains Continue, Pipeline Progresses Ahead Of AbbVie Merger
Key Allergan drugs performed well in Q3 and pipeline programs are approaching milestones as AbbVie says its $63bn acquisition of the company remains on track to close early next year.
Alexion Buys A Complementary Business With Achillion
The company agreed to pay $930m up front to acquire Achillion, which has two drugs in Phase II development for complement alternative pathway-mediated rare diseases.